JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 29, 2004; DOI: 10.1124/jpet.104.069997


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.069997v1
311/2/659    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anand, B. S
Right arrow Articles by Mitra, A. K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anand, B. S
Right arrow Articles by Mitra, A. K


Received for publication April 19, 2004.
Revised June 11, 2004.
Accepted for publication June 14, 2004.

Pharmacokinetics of Novel Dipeptide Ester Prodrugs of Acyclovir Following Oral Administration: Intestinal absorption and Liver Metabolism

Banmeet S Anand 1, Suresh Katragadda 1, Ashim K Mitra 1*

1 University of Missouri-Kansas City

* Address correspondence to: E-mail: mitraa{at}umkc.edu

Abstract

The amino acid prodrug of acyclovir (ACV), valacyclovir (VACV) is an effective anti-herpetic drug. Systemic availability of ACV in humans is 3-5 times higher after oral administration of VACV. Enhanced bioavailability of VACV has been attributed to its carrier mediated intestinal absorption, via hPEPT1 peptide transporter followed by rapid and complete conversion to ACV. An earlier report suggested that the dipeptide ester prodrugs of ACV possess high affinity towards the intestinal oligopeptide transporter hPEPT1 and therefore appear to be promising candidates in the treatment of oral herpes virus infections. In the present study we have examined the bioavailability of a series of dipeptide prodrugs of ACV following oral administration in Sprague-Dawley rats with cannulated jugular and portal veins. The area under plasma-concentration time curves (AUC) expressed as min µg ml-1 for total concentration of VACV (208.4 ± 41.2) and the dipeptide prodrugs, Gly-Val-ACV (GVACV) (416.1 ± 140.9); Val-Val-ACV (VVACV) (147.7 ± 89.3); Val-Tyr-ACV (VYACV) (180.7 ± 81.2) were significantly higher than that of ACV (21.2 ± 5.2) upon intestinal absorption. Interestingly the bioavailability of ACV after administration of GVACV was approximately 2 fold higher than VACV. There was significant metabolism by hepatic first pass effect of the dipeptide prodrugs as evident by the higher levels of ACV obtained after systemic absorption as compared to intestinal absorption of GVACV and VVACV. The dipeptide prodrugs of ACV exhibited higher systemic availability of regenerated ACV upon oral administration and thus appear to be promising drug candidates in treatment of oral and genital herpes infections.


Key words: Antivirals, Herpes, Metabolsim, Peptide Transporter, Pharmacokinetics, Prodrugs





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.